level" association) [3] . Showing that both criteria are met usually requires a meta-analysis of randomized trials, or one large trials that can be broken down in smaller units (such as participating countries). When such data are available, the predictive value of potential surrogate biomarkers can be investigated, and the "surrogate threshold effect" can be estimated as the minimum effect on the surrogate biomarker that predicts a statistically significant effect on the clinical endpoint [4] .
A very different line of research has evolved from concepts of causal inference, in particular the concept of "principal stratification", in which treatment effects on the true endpoint are estimated within strata defined by different surrogate values [5] . The conceptual elegance of this approach has not yet led to convincing applications, in large part because it has proven challenging to find good estimation methods for the counterfactual probabilities that are required to validate a surrogate [6] . It is likely, however, that causal inference will play a key role in future attempts to validate surrogate endpoints.
